Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement.

Next Previous
X
Search
Trial Profile

A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sufentanil (Primary)
  • Indications Postoperative pain
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AcelRx Pharmaceuticals; Talphera

    • Most Recent Events

    • 09 Jan 2024 According to Talphera media release, AcelRx Pharmaceuticals changed its name to Talphera, Inc.
    • 18 May 2011 Combined results from this and two other trials (NCT00859313 and NCT00718081) presented at the 30th Annual Scientific Meeting of the American Pain Society, according to a AcelRx Pharmaceuticals media release.
    • 20 Apr 2010 Actual number of patients and trial centres updated, as reported by an AcelRx Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top